izpis_h1_title_alt

Odmerjanje zdravil za zdravljenje Alzheimerjeve in Parkinsonove bolezni
Locatelli, Igor (Author), Mrhar, Aleš (Author)

URLURL - Presentation file, Visit http://www.dlib.si/details/URN:NBN:SI:doc-PHMYSJOR This link opens in a new window

Abstract
Zdravljenje Alzheimerjeve bolezni (AB) in Parkinsonove bolezni (PB) z zdravilije simptomatsko. Uvajanje terapije s temi zdravili je postopno, kar pomeni, da se terapija prične z najmanjšim odmerkom, ki se ga nato postopoma zvišuje, dokler ni dosežen zadosten klinični učinek. Zdravila prvega izbora za zdravljenje zmerne AB so zaviralci holinesteraz (donepezil, galantamin, rivastigmin), medtem ko je za zdravljenje hude oblike AB indiciran memantin, antagonist NMDA receptorjev. Zdravila prvega izbora za zdravljenje PB so dopaminergiki, od katerih je levodopa najbolj učinkovita. Starejšim bolnikom se prednostno odmerja levodopa, mlajøim bolnikom pa agoniste dopaminskih receptorjev (pramipeksol in ropinirol). Odmerjanje levodope pri napredovani PBje zahtevno, saj se za radi nadaljnjega propada nevronov terapevtsko okno levodope zoži, kar povzroči, da se že pri majhnih nihanjih plazemskih koncentracij levodope pojavijo motorični zapleti. Trenutni način, kako motorične zaplete omiliti, je razvoj novih farmacevtskih oblik, ki omogočajo t.i.dopaminergično stimulacijo.

Language:Slovenian
Keywords:Alzheimerjeva bolezen, Parkinsonova bolezen, odmerjanje zdravil, odmerjanje rivastigmina
Work type:Not categorized (r6)
Tipology:1.08 - Published Scientific Conference Contribution
Organization:FFA - Faculty of Pharmacy
Year:2008
Publisher:Slovensko farmacevtsko društvo
Number of pages:str. 79-85
Numbering:59, 2
UDC:615.2
ISSN on article:0014-8229
COBISS.SI-ID:2325361 Link is opened in a new window
Views:465
Downloads:120
Metadata:XML RDF-CHPDL DC-XML DC-RDF
 
Average score:(0 votes)
Your score:Voting is allowed only to logged in users.
:
Share:AddThis
AddThis uses cookies that require your consent. Edit consent...

Record is a part of a proceedings

Title:Simpozij ob 33. skupščini Slovenskega farmacevtksega društva, Portorož, 15.5 - 17.5.2008
COBISS.SI-ID:2331505 This link opens in a new window

Record is a part of a journal

Title:Farmacevtski vestnik
Shortened title:Farm. vestn.
Publisher:Slovensko farmacevtsko društvo
ISSN:0014-8229
COBISS.SI-ID:3105794 This link opens in a new window

Secondary language

Language:English
Title:Dosage regimens of drugs used in the treatment of Alzheimer's and Parkinson's disease
Abstract:
Pharmacotherapy of Alzheimer's (AD) and Parkinson's disease (PD) is stillinergic drugs that can provide continuous dopaminergic stimulation symptomatic. In the initiation phase of the pharmacotherapy the dose of the majority of these drugs is kept low and it should be gradually increased until the optimal clinical effect is reached. Cholinesterase inhibitors such asdonepezil, galantamine, and rivastigmine represent the first class of drugs approved for the treatment of mild to moderate AD, while memantine, a NMDA receptor antagonist, is recommended for the treatment of severe AD. Dopaminergic drugs, amongst which levodopa is the most effective, are the first class drugs approved for the treatment of PD. The treatment with levodopa is recommended for older patients, while the dopamine agonists such as pramipexol and ropinirol are used for younger patients. Progressive neurodegeneration results in narrower therapeutic window of levodopa. Consequently, even minor fluctuations in levodopa plasma concentrations can berelated to the occurrence of motor complications. Motor complications can bereduced by using new delivery systems of dopaminergic drugs that can providecontinuous dopaminergic stimulation.


Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Comments

Leave comment

You have to log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back